JW (Cayman) Therapeutics Co. Ltd. (JNY) AI Stock Analysis

0 Followers

JW (Cayman) Therapeutics Co. Ltd.

(Frankfurt:JNY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and Gross Margin GrowthThe rebound in revenue, alongside improved gross margin, indicates stronger commercial traction and better economics for the company’s cell-therapy portfolio. If sustained, this combination can expand operating leverage, support reinvestment in clinical development, and strengthen the platform’s position over the next several quarters.

Negative Factors

Deep and Persistent LossesThe company remains far from profitability despite improving revenue and narrowing losses. Persistently negative operating earnings limit internal funding for research and commercialization, increase dependence on capital markets, and make future financial performance highly sensitive to execution and product adoption.

JW (Cayman) Therapeutics Co. Ltd. (JNY) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.10B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.7
Beta (1Y): 0.81
Revenue Growth: 55.89%
EPS Growth: 47.77%
Country: Germany
Employees: 303
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model

Company Description

JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through tr...

JW (Cayman) Therapeutics Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:JNY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:9966	52Neutral	HKD 6.09B	-30.44	-10.27%	―	-31.77%	-177.01%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:2181	51Neutral	HKD 1.81B	18.26	48.25%	―	88.38%	―
HK:2171	48Neutral	HKD 6.69B	-58.83	-9.45%	―	68.12%	81.84%
HK:2616	47Neutral	HKD 8.63B	-17.27	-43.54%	―	116.67%	-0.42%
HK:1541	44Neutral	HKD 1.18B	-4.49	-32.32%	―	28.93%	27.27%

* Healthcare Sector Average

Performance Comparison

DE:JNY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:JNY	JW (Cayman) Therapeutics Co. Ltd.	0.28	-0.10	-25.79%
HK:9966	Alphamab Oncology	6.15	-3.64	-37.18%
HK:2171	CARsgen Therapeutics Holdings Ltd.	11.16	-6.73	-37.62%
HK:2181	Mabpharm Limited	0.44	-0.08	-15.38%
HK:2616	CStone Pharmaceuticals	5.48	-0.60	-9.87%
HK:1541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H	2.80	-5.11	-64.60%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

JW (Cayman) Therapeutics Co. Ltd. AI Stock Analysis